FDA Clearance Tracker · P050012
DEXCOM STS CONTINOUS MONITORS
Last checked: Nov 20, 2026Latest source record: Mar 24, 2006 (this decision)Source: openFDAMethods & limitations
Decided
Mar 24, 2006
Approval withdrawn
Time to decision
366 days
Received Mar 23, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P050012
- Device name
- DEXCOM STS CONTINOUS MONITORS
- Applicant
- Dexcom, Inc.
- Applicant location
- San Diego, CA
- Received
- Mar 23, 2005
- Decided
- Mar 24, 2006
- Decision
- Approval withdrawn
- Supplements
- 49 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE DEXCOM STS CONTINUOUS GLUCOSE MONITORING SYSTEM. THE DEVICE IS INDICATED FOR THE FOLLOWING: 1) INDICATED FOR DETECTING TRENDS AND TRACKING PATTERNS IN ADULTS (18 AND OLDER) WITH DIABETES AND IS INTENDED FOR USE BY PATIENTS AT HOME AND IN HEALTH CARE FACILITIES. THE DEVICE IS FOR PRESCRIPTION USE. 2) INDICATED FOR USE AS AN ADJUNCTIVE DEVICE TO COMPLEMENT, NOT REPLACE, INFORMATION OBTAINED FROM STANDARD HOME GLUCOSE MONITORING DEVICES. 3) AIDS IN THE DETECTION OF EPISODES OF HYPERGLYCEMIA AND HYPOGLYCEMIA, FACILITATING BOTH ACUTE AND LONG-TERM THERAPY ADJUSTMENTS, WHICH MAY MINIMIZE THESE EXCURSIONS. INTERPRETATION OF THE STS SYSTEM RESULTS SHOULD BE BASED ON THE TRENDS AND PATTERNS SEEN WITH SEVERAL SEQUENTIAL SENSOR READINGS OVER TIME.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Dexcom, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.